Human CD4
Adult
Aged
Aged, 80 and over
Amino Acid Sequence
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ immunology
Clone Cells
/ immunology
Coronavirus Nucleocapsid Proteins
/ chemistry
Cytokines
/ biosynthesis
Epitopes, T-Lymphocyte
/ chemistry
Female
Humans
Immunization, Passive
Immunodominant Epitopes
/ chemistry
Male
Middle Aged
Phosphoproteins
/ chemistry
Receptors, Antigen, T-Cell, alpha-beta
/ genetics
SARS-CoV-2
/ chemistry
Spike Glycoprotein, Coronavirus
/ chemistry
COVID-19 Serotherapy
COVID-19
SARS-CoV-2
T cell
T cell receptor
epitope
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
27
04
2021
received:
19
03
2021
accepted:
21
05
2021
pubmed:
2
6
2021
medline:
27
8
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
Since December 2019, Coronavirus disease-19 (COVID-19) has spread rapidly throughout the world, leading to a global effort to develop vaccines and treatments. Despite extensive progress, there remains a need for treatments to bolster the immune responses in infected immunocompromised individuals, such as cancer patients who recently underwent a haematopoietic stem cell transplantation. Immunological protection against COVID-19 is mediated by both short-lived neutralizing antibodies and long-lasting virus-reactive T cells. Therefore, we propose that T cell therapy may augment efficacy of current treatments. For the greatest efficacy with minimal adverse effects, it is important that any cellular therapy is designed to be as specific and directed as possible. Here, we identify T cells from COVID-19 patients with a potentially protective response to two major antigens of the SARS-CoV-2 virus, Spike and Nucleocapsid protein. By generating clones of highly virus-reactive CD4
Identifiants
pubmed: 34061349
doi: 10.1111/cei.13627
pmc: PMC8239517
doi:
Substances chimiques
Coronavirus Nucleocapsid Proteins
0
Cytokines
0
Epitopes, T-Lymphocyte
0
Immunodominant Epitopes
0
Phosphoproteins
0
Receptors, Antigen, T-Cell, alpha-beta
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
363-378Subventions
Organisme : National research network of university medicine (NUM)
Organisme : Bayerisches Staatsministerium für Bildung und Kultus, Wissenschaft und Kunst
Organisme : Wilhelm Sander-Stiftung
ID : 2020.045.1
Informations de copyright
© 2021 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.
Références
Blood. 2020 Dec 17;136(25):2905-2917
pubmed: 33331927
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
mBio. 2021 Aug 31;12(4):e0150321
pubmed: 34311582
Cell. 2020 Nov 25;183(5):1340-1353.e16
pubmed: 33096020
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Eur J Immunol. 1999 Dec;29(12):4092-101
pubmed: 10602020
Front Immunol. 2021 Jan 08;11:598402
pubmed: 33488592
Science. 2021 Jun 18;372(6548):1336-1341
pubmed: 34006597
Nat Metab. 2021 Feb;3(2):149-165
pubmed: 33536639
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Front Immunol. 2013 May 31;4:129
pubmed: 23755052
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
Trends Immunol. 2002 Nov;23(11):526-9
pubmed: 12401404
Nat Neurosci. 2021 Feb;24(2):168-175
pubmed: 33257876
Immunity. 2020 Dec 15;53(6):1258-1271.e5
pubmed: 33296686
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
J Clin Invest. 2021 May 17;131(10):
pubmed: 33822770
Clin Exp Immunol. 2021 Sep;205(3):363-378
pubmed: 34061349
Eur J Immunol. 2021 Jun;51(6):1436-1448
pubmed: 33784417
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Immunity. 2020 Dec 15;53(6):1245-1257.e5
pubmed: 33326767
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
J Clin Invest. 2021 May 17;131(10):
pubmed: 33830946
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353